Literature DB >> 3488189

The incidence and antibiotic susceptibility of Branhamella catarrhalis in respiratory infections.

M A Calder, M J Croughan, D T McLeod, F Ahmad.   

Abstract

The incidence of Branhamella catarrhalis in respiratory infections at City Hospital, Edinburgh from January 1981 to April 1984 is described. Beginning in January 1982 there was an increased incidence associated with a high proportion of beta-lactamase-producing strains. The number of these strains increased: from January 1981 to April 1983, 61% of strains produced beta-lactamase, and 83% produced beta-lactamase from January to April 1984. 53% of patients were infected in hospital. Environmental studies showed that 7% of staff and 8% of patients were carriers; there was also circumstantial evidence of ward and patient-to-patient infection. The antimicrobial susceptibility of 54 clinical strains was tested: all strains were resistant to trimethoprim but were susceptible to clavulanic acid plus amoxycillin, chloramphenicol, erythromycin, co-trimoxazole, cefotaxime and cefuroxime. beta-Lactamase-negative strains were uniformly susceptible to penicillin and ampicillin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488189     DOI: 10.2165/00003495-198600313-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  17 in total

1.  Branhamella catarrhalis.

Authors: 
Journal:  Lancet       Date:  1982-05-29       Impact factor: 79.321

2.  Antimicrobial susceptibility of Branhamella catarrhalis isolates from bronchopulmonary infections.

Authors:  F Ahmad; D T McLeod; M J Croughan; M A Calder
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

3.  Urinary tract infection caused by Branhamella catarrhalis.

Authors:  F Ahmad; M A Calder; M J Croughan; T G Marshall
Journal:  J Infect       Date:  1985-03       Impact factor: 6.072

4.  In vitro sensitivity to penicillin V and beta-lactamase production of Branhamella catarrhalis.

Authors:  B E Malmvall; J E Brorsson; J Johnsson
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

5.  Pathogenicity of and beta-lactamase production by Branhamella (Neisseria) catarrhalis.

Authors:  A Percival; J E Corkill; J Rowlands; R B Sykes
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

6.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

7.  Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.

Authors:  N J Slevin; J Aitken; P E Thornley
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

8.  Bronchopulmonary infection due to Branhamella catarrhalis.

Authors:  D T McLeod; F Ahmad; J T Power; M A Calder; A Seaton
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-12

9.  Branhamella catarrhalis: antibiotic sensitivities and beta-lactamases.

Authors:  E E Stobberingh; B I Davies; C P van Boven
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

10.  Comparison of trimethoprim alone with trimethoprim sulphamethoxazole in the treatment of respiratory and urinary infections with particular reference to selection of trimethoprim resistance.

Authors:  R W Lacey; V L Lord; H K Gunasekera; P J Leiberman; D E Luxton
Journal:  Lancet       Date:  1980-06-14       Impact factor: 79.321

View more
  11 in total

1.  Labile type-specific antigen of Moraxella catarrhalis.

Authors:  S J Norkus; J W Vennes
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

2.  The other siblings: respiratory infections caused by Moraxella catarrhalis and Haemophilus influenzae.

Authors:  Larry Lutwick; Laila Fernandes
Journal:  Curr Infect Dis Rep       Date:  2006-05       Impact factor: 3.725

3.  Bactericidal activity of BMY-28100 versus amoxicillin/clavulanic acid against Branhamella catarrhalis.

Authors:  E Yourassowsky; M P Van der Linden; M J Lismont; F Crokaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

4.  Pulmonary thin-section CT findings in acute Moraxella catarrhalis pulmonary infection.

Authors:  F Okada; Y Ando; T Nakayama; S Tanoue; R Ishii; A Ono; M Watanabe; H Takaki; T Maeda; H Mori
Journal:  Br J Radiol       Date:  2010-12-01       Impact factor: 3.039

Review 5.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Clinical features fail to distinguish respiratory infections caused by Branhamella catarrhalis from those caused by Haemophilus influenzae.

Authors:  K R Forward
Journal:  Can J Infect Dis       Date:  1992-01

Review 7.  Branhamella catarrhalis: an organism gaining respect as a pathogen.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

8.  Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.

Authors:  J H Jorgensen; G V Doern; L A Maher; A W Howell; J S Redding
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 9.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

10.  Evaluation of amoxicillin clavulanate twice daily versus thrice daily in the treatment of otitis media in children. Danish-Swedish Study Group.

Authors:  S Jacobsson; A Fogh; P Larsson; S Lomborg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.